Prefrontal synaptic markers of cocaine addiction-like behavior in rats.
Identifieur interne : 001564 ( Main/Corpus ); précédent : 001563; suivant : 001565Prefrontal synaptic markers of cocaine addiction-like behavior in rats.
Auteurs : F. Kasanetz ; M. Lafourcade ; V. Deroche-Gamonet ; J-M Revest ; N. Berson ; E. Balado ; J-F Fiancette ; P. Renault ; P-V Piazza ; O J ManzoniSource :
- Molecular psychiatry [ 1476-5578 ] ; 2013.
English descriptors
- KwdEn :
- Amino Acids (pharmacology), Analysis of Variance (MeSH), Animals (MeSH), Biophysics (MeSH), Bridged Bicyclo Compounds, Heterocyclic (pharmacology), Cocaine (administration & dosage), Cocaine (adverse effects), Conditioning, Operant (drug effects), Disease Models, Animal (MeSH), Dopamine Uptake Inhibitors (administration & dosage), Dopamine Uptake Inhibitors (adverse effects), Electric Stimulation (MeSH), Excitatory Amino Acid Agonists (pharmacology), Excitatory Postsynaptic Potentials (drug effects), In Vitro Techniques (MeSH), Long-Term Synaptic Depression (drug effects), Male (MeSH), Patch-Clamp Techniques (MeSH), Prefrontal Cortex (metabolism), Prefrontal Cortex (pathology), Psychiatric Status Rating Scales (MeSH), Rats (MeSH), Rats, Sprague-Dawley (MeSH), Receptors, AMPA (metabolism), Receptors, N-Methyl-D-Aspartate (metabolism), Self Administration (MeSH), Substance-Related Disorders (metabolism), Substance-Related Disorders (pathology), Substance-Related Disorders (psychology), Synapses (drug effects), Synapses (metabolism).
- MESH :
- chemical , administration & dosage : Cocaine, Dopamine Uptake Inhibitors.
- chemical , adverse effects : Cocaine, Dopamine Uptake Inhibitors.
- chemical , metabolism : Receptors, AMPA, Receptors, N-Methyl-D-Aspartate.
- chemical , pharmacology : Amino Acids, Bridged Bicyclo Compounds, Heterocyclic, Excitatory Amino Acid Agonists.
- drug effects : Conditioning, Operant, Excitatory Postsynaptic Potentials, Long-Term Synaptic Depression, Synapses.
- metabolism : Prefrontal Cortex, Substance-Related Disorders, Synapses.
- pathology : Prefrontal Cortex, Substance-Related Disorders.
- psychology : Substance-Related Disorders.
- Analysis of Variance, Animals, Biophysics, Disease Models, Animal, Electric Stimulation, In Vitro Techniques, Male, Patch-Clamp Techniques, Psychiatric Status Rating Scales, Rats, Rats, Sprague-Dawley, Self Administration.
Abstract
Defining the drug-induced neuroadaptations specifically associated with the behavioral manifestation of addiction is a daunting task. To address this issue, we used a behavioral model that differentiates rats controlling their drug use (Non-Addict-like) from rats undergoing transition to addiction (Addict-like). Dysfunctions in prefrontal cortex (PFC) synaptic circuits are thought to be responsible for the loss of control over drug taking that characterizes addicted individuals. Here, we studied the synaptic alterations in prelimbic PFC (pPFC) circuits associated with transition to addiction. We discovered that some of the changes induced by cocaine self-administration (SA), such as the impairment of the endocannabinoid-mediated long-term synaptic depression (eCB-LTD) was similarly abolished in Non-Addict- and Addict-like rats and thus unrelated to transition to addiction. In contrast, metabotropic glutamate receptor 2/3-mediated LTD (mGluR2/3-LTD) was specifically suppressed in Addict-like rats, which also show a concomitant postsynaptic plasticity expressed as a change in the relative contribution of AMPAR and NMDAR to basal glutamate-mediated synaptic transmission. Addiction-associated synaptic alterations in the pPFC were not fully developed at early stages of cocaine SA, when addiction-like behaviors are still absent, suggesting that pathological behaviors appear once the pPFC is compromised. These data identify specific synaptic impairments in the pPFC associated with addiction and support the idea that alterations of synaptic plasticity are core markers of drug dependence.
DOI: 10.1038/mp.2012.59
PubMed: 22584869
Links to Exploration step
pubmed:22584869Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Prefrontal synaptic markers of cocaine addiction-like behavior in rats.</title><author><name sortKey="Kasanetz, F" sort="Kasanetz, F" uniqKey="Kasanetz F" first="F" last="Kasanetz">F. Kasanetz</name><affiliation><nlm:affiliation>INSERM, Neurocentre Magendie, Physiopathologie de la Plasticité Neuronale, Bordeaux, France.</nlm:affiliation></affiliation></author><author><name sortKey="Lafourcade, M" sort="Lafourcade, M" uniqKey="Lafourcade M" first="M" last="Lafourcade">M. Lafourcade</name></author><author><name sortKey="Deroche Gamonet, V" sort="Deroche Gamonet, V" uniqKey="Deroche Gamonet V" first="V" last="Deroche-Gamonet">V. Deroche-Gamonet</name></author><author><name sortKey="Revest, J M" sort="Revest, J M" uniqKey="Revest J" first="J-M" last="Revest">J-M Revest</name></author><author><name sortKey="Berson, N" sort="Berson, N" uniqKey="Berson N" first="N" last="Berson">N. Berson</name></author><author><name sortKey="Balado, E" sort="Balado, E" uniqKey="Balado E" first="E" last="Balado">E. Balado</name></author><author><name sortKey="Fiancette, J F" sort="Fiancette, J F" uniqKey="Fiancette J" first="J-F" last="Fiancette">J-F Fiancette</name></author><author><name sortKey="Renault, P" sort="Renault, P" uniqKey="Renault P" first="P" last="Renault">P. Renault</name></author><author><name sortKey="Piazza, P V" sort="Piazza, P V" uniqKey="Piazza P" first="P-V" last="Piazza">P-V Piazza</name></author><author><name sortKey="Manzoni, O J" sort="Manzoni, O J" uniqKey="Manzoni O" first="O J" last="Manzoni">O J Manzoni</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013</date><idno type="RBID">pubmed:22584869</idno><idno type="pmid">22584869</idno><idno type="doi">10.1038/mp.2012.59</idno><idno type="wicri:Area/Main/Corpus">001564</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001564</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Prefrontal synaptic markers of cocaine addiction-like behavior in rats.</title><author><name sortKey="Kasanetz, F" sort="Kasanetz, F" uniqKey="Kasanetz F" first="F" last="Kasanetz">F. Kasanetz</name><affiliation><nlm:affiliation>INSERM, Neurocentre Magendie, Physiopathologie de la Plasticité Neuronale, Bordeaux, France.</nlm:affiliation></affiliation></author><author><name sortKey="Lafourcade, M" sort="Lafourcade, M" uniqKey="Lafourcade M" first="M" last="Lafourcade">M. Lafourcade</name></author><author><name sortKey="Deroche Gamonet, V" sort="Deroche Gamonet, V" uniqKey="Deroche Gamonet V" first="V" last="Deroche-Gamonet">V. Deroche-Gamonet</name></author><author><name sortKey="Revest, J M" sort="Revest, J M" uniqKey="Revest J" first="J-M" last="Revest">J-M Revest</name></author><author><name sortKey="Berson, N" sort="Berson, N" uniqKey="Berson N" first="N" last="Berson">N. Berson</name></author><author><name sortKey="Balado, E" sort="Balado, E" uniqKey="Balado E" first="E" last="Balado">E. Balado</name></author><author><name sortKey="Fiancette, J F" sort="Fiancette, J F" uniqKey="Fiancette J" first="J-F" last="Fiancette">J-F Fiancette</name></author><author><name sortKey="Renault, P" sort="Renault, P" uniqKey="Renault P" first="P" last="Renault">P. Renault</name></author><author><name sortKey="Piazza, P V" sort="Piazza, P V" uniqKey="Piazza P" first="P-V" last="Piazza">P-V Piazza</name></author><author><name sortKey="Manzoni, O J" sort="Manzoni, O J" uniqKey="Manzoni O" first="O J" last="Manzoni">O J Manzoni</name></author></analytic><series><title level="j">Molecular psychiatry</title><idno type="eISSN">1476-5578</idno><imprint><date when="2013" type="published">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Amino Acids (pharmacology)</term><term>Analysis of Variance (MeSH)</term><term>Animals (MeSH)</term><term>Biophysics (MeSH)</term><term>Bridged Bicyclo Compounds, Heterocyclic (pharmacology)</term><term>Cocaine (administration & dosage)</term><term>Cocaine (adverse effects)</term><term>Conditioning, Operant (drug effects)</term><term>Disease Models, Animal (MeSH)</term><term>Dopamine Uptake Inhibitors (administration & dosage)</term><term>Dopamine Uptake Inhibitors (adverse effects)</term><term>Electric Stimulation (MeSH)</term><term>Excitatory Amino Acid Agonists (pharmacology)</term><term>Excitatory Postsynaptic Potentials (drug effects)</term><term>In Vitro Techniques (MeSH)</term><term>Long-Term Synaptic Depression (drug effects)</term><term>Male (MeSH)</term><term>Patch-Clamp Techniques (MeSH)</term><term>Prefrontal Cortex (metabolism)</term><term>Prefrontal Cortex (pathology)</term><term>Psychiatric Status Rating Scales (MeSH)</term><term>Rats (MeSH)</term><term>Rats, Sprague-Dawley (MeSH)</term><term>Receptors, AMPA (metabolism)</term><term>Receptors, N-Methyl-D-Aspartate (metabolism)</term><term>Self Administration (MeSH)</term><term>Substance-Related Disorders (metabolism)</term><term>Substance-Related Disorders (pathology)</term><term>Substance-Related Disorders (psychology)</term><term>Synapses (drug effects)</term><term>Synapses (metabolism)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Cocaine</term><term>Dopamine Uptake Inhibitors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Cocaine</term><term>Dopamine Uptake Inhibitors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Receptors, AMPA</term><term>Receptors, N-Methyl-D-Aspartate</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Amino Acids</term><term>Bridged Bicyclo Compounds, Heterocyclic</term><term>Excitatory Amino Acid Agonists</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Conditioning, Operant</term><term>Excitatory Postsynaptic Potentials</term><term>Long-Term Synaptic Depression</term><term>Synapses</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Prefrontal Cortex</term><term>Substance-Related Disorders</term><term>Synapses</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Prefrontal Cortex</term><term>Substance-Related Disorders</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Substance-Related Disorders</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Analysis of Variance</term><term>Animals</term><term>Biophysics</term><term>Disease Models, Animal</term><term>Electric Stimulation</term><term>In Vitro Techniques</term><term>Male</term><term>Patch-Clamp Techniques</term><term>Psychiatric Status Rating Scales</term><term>Rats</term><term>Rats, Sprague-Dawley</term><term>Self Administration</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Defining the drug-induced neuroadaptations specifically associated with the behavioral manifestation of addiction is a daunting task. To address this issue, we used a behavioral model that differentiates rats controlling their drug use (Non-Addict-like) from rats undergoing transition to addiction (Addict-like). Dysfunctions in prefrontal cortex (PFC) synaptic circuits are thought to be responsible for the loss of control over drug taking that characterizes addicted individuals. Here, we studied the synaptic alterations in prelimbic PFC (pPFC) circuits associated with transition to addiction. We discovered that some of the changes induced by cocaine self-administration (SA), such as the impairment of the endocannabinoid-mediated long-term synaptic depression (eCB-LTD) was similarly abolished in Non-Addict- and Addict-like rats and thus unrelated to transition to addiction. In contrast, metabotropic glutamate receptor 2/3-mediated LTD (mGluR2/3-LTD) was specifically suppressed in Addict-like rats, which also show a concomitant postsynaptic plasticity expressed as a change in the relative contribution of AMPAR and NMDAR to basal glutamate-mediated synaptic transmission. Addiction-associated synaptic alterations in the pPFC were not fully developed at early stages of cocaine SA, when addiction-like behaviors are still absent, suggesting that pathological behaviors appear once the pPFC is compromised. These data identify specific synaptic impairments in the pPFC associated with addiction and support the idea that alterations of synaptic plasticity are core markers of drug dependence.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22584869</PMID><DateCompleted><Year>2014</Year><Month>01</Month><Day>03</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5578</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>6</Issue><PubDate><Year>2013</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Molecular psychiatry</Title><ISOAbbreviation>Mol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Prefrontal synaptic markers of cocaine addiction-like behavior in rats.</ArticleTitle><Pagination><MedlinePgn>729-37</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/mp.2012.59</ELocationID><Abstract><AbstractText>Defining the drug-induced neuroadaptations specifically associated with the behavioral manifestation of addiction is a daunting task. To address this issue, we used a behavioral model that differentiates rats controlling their drug use (Non-Addict-like) from rats undergoing transition to addiction (Addict-like). Dysfunctions in prefrontal cortex (PFC) synaptic circuits are thought to be responsible for the loss of control over drug taking that characterizes addicted individuals. Here, we studied the synaptic alterations in prelimbic PFC (pPFC) circuits associated with transition to addiction. We discovered that some of the changes induced by cocaine self-administration (SA), such as the impairment of the endocannabinoid-mediated long-term synaptic depression (eCB-LTD) was similarly abolished in Non-Addict- and Addict-like rats and thus unrelated to transition to addiction. In contrast, metabotropic glutamate receptor 2/3-mediated LTD (mGluR2/3-LTD) was specifically suppressed in Addict-like rats, which also show a concomitant postsynaptic plasticity expressed as a change in the relative contribution of AMPAR and NMDAR to basal glutamate-mediated synaptic transmission. Addiction-associated synaptic alterations in the pPFC were not fully developed at early stages of cocaine SA, when addiction-like behaviors are still absent, suggesting that pathological behaviors appear once the pPFC is compromised. These data identify specific synaptic impairments in the pPFC associated with addiction and support the idea that alterations of synaptic plasticity are core markers of drug dependence.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kasanetz</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>INSERM, Neurocentre Magendie, Physiopathologie de la Plasticité Neuronale, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lafourcade</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Deroche-Gamonet</LastName><ForeName>V</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Revest</LastName><ForeName>J-M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Berson</LastName><ForeName>N</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Balado</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Fiancette</LastName><ForeName>J-F</ForeName><Initials>JF</Initials></Author><Author ValidYN="Y"><LastName>Renault</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Piazza</LastName><ForeName>P-V</ForeName><Initials>PV</Initials></Author><Author ValidYN="Y"><LastName>Manzoni</LastName><ForeName>O J</ForeName><Initials>OJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>05</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Psychiatry</MedlineTA><NlmUniqueID>9607835</NlmUniqueID><ISSNLinking>1359-4184</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000596">Amino Acids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019086">Bridged Bicyclo Compounds, Heterocyclic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018765">Dopamine Uptake Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018690">Excitatory Amino Acid Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C118218">LY 379268</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018091">Receptors, AMPA</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016194">Receptors, N-Methyl-D-Aspartate</NameOfSubstance></Chemical><Chemical><RegistryNumber>I5Y540LHVR</RegistryNumber><NameOfSubstance UI="D003042">Cocaine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000596" MajorTopicYN="N">Amino Acids</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001703" MajorTopicYN="N">Biophysics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019086" MajorTopicYN="N">Bridged Bicyclo Compounds, Heterocyclic</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003042" MajorTopicYN="N">Cocaine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003216" MajorTopicYN="N">Conditioning, Operant</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018765" MajorTopicYN="N">Dopamine Uptake Inhibitors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004558" MajorTopicYN="N">Electric Stimulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018690" MajorTopicYN="N">Excitatory Amino Acid Agonists</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019706" MajorTopicYN="N">Excitatory Postsynaptic Potentials</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036881" MajorTopicYN="N">Long-Term Synaptic Depression</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018408" MajorTopicYN="N">Patch-Clamp Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017397" MajorTopicYN="N">Prefrontal Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018091" MajorTopicYN="N">Receptors, AMPA</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016194" MajorTopicYN="N">Receptors, N-Methyl-D-Aspartate</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012646" MajorTopicYN="N">Self Administration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019966" MajorTopicYN="N">Substance-Related Disorders</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>5</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>5</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>1</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22584869</ArticleId><ArticleId IdType="pii">mp201259</ArticleId><ArticleId IdType="doi">10.1038/mp.2012.59</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/AutomedicationFrancoV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001564 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001564 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= AutomedicationFrancoV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:22584869
|texte= Prefrontal synaptic markers of cocaine addiction-like behavior in rats.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:22584869" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AutomedicationFrancoV1
| This area was generated with Dilib version V0.6.38. |  |